View Author
patient sarcoma study cancer imatinib tissue survival factor response treatment tumor group trial prognostic analysis bone sarcoma group disease tissue sarcoma grade progression chemotherapy prognostic factors table phase month model therapy stromal tumors stromal eortc doxorubicin result criteria tissue sarcomas research metastase european status tumours liver performance status level liver metastases recist oncol agent resistance lesion mutation toxicity metastatic chapter expression smoking regimen survival time count performance response rate multivariate lymphopenia activity ifosfamide diagnosis value progression-free survival 5 years univariate baseline phase ii trials number verweij progression-free series angiosarcoma prognostic value tumour toxicitie leiomyosarcoma event
9 Most Recent Publications
|
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)
(Article)
Sleijfer, S. Ouali, M. Glabbeke, M.M.B. van Krarup-Hansen, A. Rodenhuis, S. Cesne, A. le Hogendoorn, P.C.W. Verweij, J. Blay, J-Y. |
2010-01-01
|
|
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
(Article)
Ray-Coquard, I. Cropet, C. Guastalla, J.P. Bachelot, T. Perol, D. Chabaud, S. Hogendoorn, P.C.W. Cassier, P. Dufresne, A. Blay, J-Y. Glabbeke, M.M.B. van Sebban, C. Cesne, A. le Judson, I.R. Tredan, O. Verweij, J. Biron, P. Labidi, I. |
2009-07-01
|
|
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors
(Article)
Romeo, S. Debiec-Rychter, M. Sciot, R. Blay, J-Y. Hogendoorn, P.C.W. Glabbeke, M.M.B. van Paassen, H. van Comite, P. Eijk, R. van Oosting, J. Verweij, J. Terrier, P. Schneider, U. |
2009-06-15
|
|
Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC
(Article)
Erp, N.P. van Gelderblom, H. Glabbeke, M.M.B. van Oosterom, A. van Verweij, J. Guchelaar, H.J. Debiec-Rychter, M. Peng, B. Blay, J-Y. Judson, I.R. |
2008-12-15
|
|
Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group
(Article)
Schlemmer, M. Reichardt, P. Verweij, J. Hartmann, J.T. Judson, I.R. Thyss, A. Hoogendoorn, P.C.W. Marreaud, S. Glabbeke, M.M.B. van Blay, J-Y. |
2008-11-01
|
|
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate
(Article)
Sciot, R. Debiec-Rychter, M. Daugaard, S. Fisher, C. Collin, F. Glabbeke, M.M.B. van Verweij, J. Blay, J-Y. Hoogendoorn, P.C.W. |
2008-09-01
|
|
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005
(Article)
Verweij, J. Casali, P.G. Kotasek, D. Cesne, A. le Reichard, P. Judson, I.R. Issels, R.D. Oosterom, A. van Glabbeke, M.M.B. van Blay, J-Y. |
2007-04-01
|
|
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
(Article)
Leahy, M. Ray-Coquard, I. Judson, I.R. Blay, J-Y. Verweij, J. Cesne, A. le Duffaud, F. Hogendoorn, P.C.W. Fowst, C. Balincourt, C. de Paola, E.D. di Glabbeke, M.M.B. van |
2007-01-01
|
|
Advanced soft tissue sarcoma: prognostic factors and aspects of trial methodology
(Doctoral Thesis)
Glabbeke, M.M.B. van |
2006-06-08
|
